JDD Special Focus

Acne Supplements

Stay up-to-date on new clinical findings on Acne. View the latest articles, case reports, editorial features, supplements, Podcast episodes and more!

 

Supplements

Topical Acne Treatment: What’s Behind the Scenes in 2024

Optimal topical acne treatments should ideally target multiple pathways involved in acne development.2  Traditional treatments, though often effective, may come with limitations such as skin irritation, dryness, or other adverse effects. Thus, the pursuit of optimal topical acne treatments is critical to enhancing efficacy, minimizing side effects, and improving patient adherence and satisfaction.

Read More

Advancements in Topical Combination Products for Acne Treatment

Antibiotic resistance and treatment adherence remain significant challenges for acne treatment. Advances in topical formulations have ushered in an era of fixed combination topical therapeutics that are well-tolerated and more efficacious. In addition, their once-daily application leads to increased treatment adherence. This article discusses formulation strategies that allow for the coadministration of active drugs and reviews all commercially available fixed-combination topical acne treatments.

Read More

Tretinoin Formulation: From Microsponges to Polymeric Emulsion

The history of tretinoin and its use in dermatology is a testament both to the drug’s well-established efficacy and its potential to cause skin irritation. Over more than four decades, the drug that launched the retinoid class into the market has been used in the topical management of acne, either alone or in combination.

Read More

Targeting Acne Pathogenesis with Topical Therapies

We, as dermatologists, are exceedingly lucky.  We can watch our patients improve before our eyes. In clinical practice, we don’t often track a quantitative metric to gauge success but rather measure the success of our treatment by the appearance of our patients’ skin.

Read More

Sponsored

Podcast Episodes

Ask the Investigator: Acne, OCPs, and a Side Order of Practical Pearls for the Adolescent Patient

JDD Podcast host Dr. Adam Friedman gets first-hand insight from internationally acclaimed pediatric dermatologist Dr. Lawrence Eichenfield on his recent study entitled “Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients” published in the June 2016 edition of the Journal of Drugs of Dermatology. Want a refresher on the use of OCPs in Acne?

Interested in learning how to initiate a patient based survey study? Just curious how a leader in the field gets an uninterested adolescent to be compliant and engaged in his/her acne care? These are just a few of the practical pearls provided.

Listen Now

Sponsored

Featured Case Report

Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study

There is a need for new oral antibiotics for acne with improved safety profiles and targeted antibacterial spectra. Sarecycline is a novel, tetracycline-class antibiotic specifically designed for acne, offering a narrow spectrum of activity compared with currently available tetracyclines, including less activity against enteric Gram-negative bacteria. This phase 2 study evaluated the efficacy and safety of three doses of sarecycline for moderate to severe facial acne vulgaris.

 

Read Now

Featured Editorial

Virtual Exams No Substitute for In-Person Care of Acne and Rosacea

Some dermatologists may be surprised to hear that the concept of teledermatology originated 25 years ago, and has slowly increased in usage, primarily for the purpose of providing care to those in underserved areas.1 The challenges created by the COVID19 pandemic has rapidly accelerated both interest and usage of telemedicine by dermatologists, with the American Academy of Dermatology and other dedicated groups responding quickly to provide guidance on how to integrate teledermatology into real-world dermatology practice effectively, and hopefully with avoidance of technical, medicolegal, and financial pitfalls.2
Read Now

Dermatology News

Journal of Drugs in Dermatology JDD Article About The Comparison Between Conventional Photodynamic Therapy and “Painless” Photodynamic Therapy in the Treatment of Actinic Keratosis: A Mini ReviewFeatured ArticlesLatest NewsSkin CancerThe Latest
May 17, 2025

The Comparison Between Conventional Photodynamic Therapy and “Painless” Photodynamic Therapy in the Treatment of Actinic Keratosis: A Mini Review

Painless™ PDT vs. Conventional PDT: A Quick Look at Patient Comfort in AK Treatment Actinic keratosis (AK) is one of the most common conditions treated by dermatologists, and photodynamic therapy…
Journal of Drugs in Dermatology JDD Article About Exploring the Scope of Melanoma Educational Content on InstagramFeatured ArticlesLatest NewsSkin CancerThe Latest
May 16, 2025

Exploring the Scope of Melanoma Educational Content on Instagram

Melanoma Education on Instagram: What’s Missing—Especially for Skin of Color As melanoma rates rise, with a projected 7.3% increase in new cases and 3.8% rise in mortality in 2024, the…
Journal of Drugs in Dermatology JDD Article About Squamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs SurgeryFeatured ArticlesLatest NewsSkin CancerThe Latest
May 15, 2025

Squamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs Surgery

What to Expect When Treating SCC In Situ with Mohs Surgery While squamous cell carcinoma in situ (SCCIS) is typically considered a low-risk skin cancer, treatment decisions, especially around surgical…
Journal of Drugs in Dermatology JDD Article About Endocrine Mucin Producing Sweat Gland Carcinoma Treated With Mohs Micrographic Surgery: A Systematic ReviewFeatured ArticlesLatest NewsSkin CancerThe Latest
May 14, 2025

Endocrine Mucin Producing Sweat Gland Carcinoma Treated With Mohs Micrographic Surgery: A Systematic Review

EMPSGC: Why Mohs Might Be the Better Choice Endocrine Mucin Producing Sweat Gland Carcinoma (EMPSGC) is rare, low-grade, and slow-growing—but it’s not without risk. Though uncommon, recurrence and even distant…